Pharmaceutical & Biotech Weekly Report: Collaborative Innovation and M&A Expansion Highlight Opportunities in AI+Healthcare

Key Views

XtalPi Receives Second Payment from DoveTree as First Oncology Project AdvancesRecently, XtalPi achieved significant progress in its strategic collaboration with innovative biopharmaceutical company DoveTree and received the second milestone payment. Since the two parties entered into a collaboration agreement with a potential total value of up to $5.99 billion last June, their joint efforts have continued to yield substantial results. All patents related to the pipeline covered by the previous $51 million upfront payment have been fully transferred to DoveTree. One preclinical candidate (PCC) has advanced into IND-enabling studies ahead of schedule. Under the agreement, XtalPi has received a second payment of $19 million. This collaboration leverages DoveTree’s expertise in target biology and translational medicine, combined with XtalPi’s platform capabilities in computation- and automation-enabled drug discovery. Moving forward, both parties will further deepen their drug discovery cooperation around established priority areas and continue to accelerate the translation of projects from early discovery to clinical development.

Insilico Medicine and Yituo Pharma Deepen Collaboration to Advance Development of Skin Anti-Aging DrugsRecently, Insilico Medicine signed an expanded strategic cooperation agreement with Wuxi Yituo Pharmaceutical Technology Co., Ltd. Building on the phased deliverables achieved in their existing collaboration on the development of small-molecule proteolysis-targeting chimera (PROTAC) candidates against oncology targets, both parties will further expand the scope of cooperation to focus on AI-enabled innovation in skin management and the development of novel anti-aging therapeutics.The global market for skin management and anti-aging solutions is experiencing rapid growth. According to Fortune Business Insights, the global skincare market size reached USD 122.11 billion in 2025 and is projected to exceed USD 227.13 billion by 2034. Despite this prosperous market expansion, significant unmet clinical needs remain prominent. Most commercially available products are limited to ingredient formulation and superficial repair, leaving a substantial gap for innovative drugs capable of intervening in the aging process at the cellular and molecular levels while offering both high potency and high safety profiles.This collaboration between Insilico Medicine and Yituo Pharma will integrate their respective cutting-edge technological advantages to create a new R&D model featuring synergistic innovation through an “AI-enabled biology + LLPS-based small-molecule drug discovery platform.” Specifically, Insilico Medicine will utilize its PandaOmics platform to identify and screen novel targets and biomarkers associated with skin aging, and leverage the cross-species, multimodal, and multi-omics virtual data generation capabilities of its Precious GPT series to empower research into the aging process. Meanwhile, Yituo Pharma, relying on its proprietary LLPS-based drug discovery platform and extensive experience in drug R&D, will apply its comprehensive end-to-end capabilities—including target validation, pharmacological experiments, efficacy evaluation, and preclinical development—to jointly accelerate the design, screening, and development of skin anti-aging drugs.

Yidu Tech Plans to Acquire Online Doctor Platform for RMB 400 MillionOn June 1, Yidu Tech, a leading AI healthcare company, issued a voluntary announcement stating its intention to acquire 100% equity interest in an online doctor platform for approximately RMB 400 million. It is understood that the platform has accumulated a user base of approximately 3.5 million licensed physicians. The two parties signed a non-binding memorandum of understanding on May 29, with the counterparty being an independent third party. The final transaction consideration, amounting to approximately RMB 400 million, remains subject to due diligence and the definitive agreements. Upon completion of the acquisition, the target company will be consolidated into Yidu Tech’s financial statements.

Investment Recommendations

We believe that the “AI+” initiative has been explicitly incorporated into the policy framework of the 15th Five-Year Plan. AI-pharma companies continue to collaborate on innovation, advancing pipeline expansion and strategic positioning in key therapeutic areas, with a focus on projects

Key milestones such as progress and integration present opportunities. Recommended companies to watch include: XtalPi Holdings, Insilico Medicine, and Yidu Tech.

Risk Warning

Risks of price reductions for drugs and consumables; risks associated with changes in industry policies; risks of intensified market competition, etc.